🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial

Nature Communications(2025)10.1038/s41467-024-55200-2Source: DataRank Database

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial is a research paper published in Nature Communications (2025). On theSindex it has a DataRank of 0. It has been cited 18 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 21.64)OA: goldTopics (58)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (24)

Dmitriy Zamarin ORCID,Wei Deng ORCID,Heather A. Lankes ORCID,Giulio Pesci,Hayeon Kim ORCID

Live enrichment

PubMed:39788967 PMC:PMC11718273 OpenAlex:https://openalex.org/W4406199602

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: NRG Oncology U10CA180822 (NRG Oncology Statistics and Data Management Center)

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: U10CA180868 (NRG Oncology Operations),

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: P30-CA008748

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: R01CA276087

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: R50CA282102-01

NCI NIH HHS

Grant: P50 CA098252

NCI NIH HHS

Grant: U24 CA196067

NCI NIH HHS

Grant: UG1 CA233331

NCI NIH HHS

Grant: P30 CA013148

NCI NIH HHS

Grant: U10 CA180868

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: R50 CA282102

NCI NIH HHS

Grant: U10 CA180822

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5U24CA196067-04

NRG Oncology Biospecimen Bank

National Institutes of Health

Grant: 5U10CA180868-09

NRG Oncology Network Group Operations Center

National Institutes of Health

Grant: 5R50CA282102-03

NCI Clinical Trial Research Strategy, Harnessing Innovation, and Implementation

National Institutes of Health

Grant: 7R01CA276087-02

Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation

National Institutes of Health

Grant: 2U10CA180822-06

NRG Oncology - Statistical and Data Management Center

FWCI

21.64

Citation Percentile

1.0%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://www.nature.com/articles/s41467-024-55200-2.pdf

publisherhttps://www.nature.com/articles/s41467-024-55200-2.pdf

publisherhttps://www.nature.com/articles/s41467-024-55200-2

journalhttps://doi.org/10.1038/s41467-024-55200-2

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39788967

Fields of Study

Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersColorectal and Anal Carcinomas03 medical and health sciences0302 clinical medicine

MeSH Terms

Immune Checkpoint InhibitorsAdultAgedUterine Cervical NeoplasmsFemaleHumansMiddle AgedNeoplasm StagingReceptors, Antigen, T-CellDisease-Free SurvivalNeoadjuvant TherapyChemoradiotherapyB7-H1 AntigenAntibodies, Monoclonal, Humanized

Keywords

AtezolizumabMedicineClinical endpointOncologyInternal medicineCervical cancerRandomized controlled trialNeoadjuvant therapySurrogate endpointCancerUrologyNivolumabImmunotherapyBreast cancerAdultdisease-free survivalScienceReceptors, Antigen, T-Cellmonoclonalreceptors610Uterine Cervical NeoplasmsAntibodies, Monoclonal, HumanizedArticleB7-H1 Antigenchemoradiotherapyimmune checkpoint inhibitorsantigenmiddle agedt-cellMedical SpecialtiesMedicine and Health SciencesantibodiesHumansneoplasm stagingAgedhumanizedQfemale

Sustainable Development Goals

SDG 0: Good health and well-being